Amit Patel, Senior Vice President & Head–North America Generics
At Dr. Reddy’s, we understand that every customer has a choice of products, as well as a choice of where to acquire them. Knowing this, we strive to provide quality products at the best value every day. Our ultimate goal is to provide affordable and innovative medicines for healthier lives.
Dr. Reddy’s began marketing finished dosage form products in the United States in 2001. Today, under the Dr. Reddy’s label, 45 prescription products are marketed in 179 dosing presentations, with 25 ranked “top 3” in market share. Our Private Label OTC Group, established in 2007, markets 10 products in 200 store brand packaging presentations. We are also uniquely positioned to support Rx-to OTC switches through our OTC group.
Vertical integration helps provide a smoother transition from manufacturing to market. Our regulatory-compliant manufacturing facilities follow cGMP guidelines in the production of finished dosage forms. Dr. Reddy’s has 4 FDA-approved finished dosage facilities servicing the United States and 8 FDA-inspected API facilities across the globe. Plans for additional dosage forms, including injectables, liquids, biologicals, and topicals, are also under way. Dr. Reddy’s has 76 ANDAs pending approval, of which 38 are Para IV certifications and 10 are FTFs. Amid changing market conditions and industry cycles, Dr. Reddy’s strives to lead the way—reining in the health care costs and improving access to medications across the United States. PT
For more information, visit www.drreddys.com.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs